文献速递骨软组织肉瘤与黑色素瘤

达拉非尼联合曲美替尼间歇给药对比连续给药治疗BRAFV600突变晚期黑色素瘤的随机2期研究(INTERIM)

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).
PubMed 文献 · Eur J Cancer · 2023-11-24

INTERIM是一项2期随机试验,将79例计划开始达拉非尼联合曲美替尼治疗的BRAFV600突变晚期黑色素瘤患者随机分为连续给药组(40例)和间歇给药组(39例,达拉非尼第1-21天、曲美替尼第1-14天,每28天为一周期)。中位随访19个月,间歇给药组在所有疗效指标上均劣于连续给药组:中位无进展生存期8.5个月 vs 10.7个月(HR 1.39,95%CI 0.79-2.45,p=0.255),中位总生存期18.1个月 vs 未达到(HR 1.69,95%CI 0.87-3.28,p=0.121),客观缓解率57% vs 77%。结论与近期其他临床试验一致,即间歇给药未能改善BRAF+MEK抑制剂的疗效。

要点

  • 间歇给药组中位无进展生存期8.5个月 vs 连续给药组10.7个月(HR 1.39,95%CI 0.79-2.45,p=0.255)。
  • 间歇给药组中位总生存期18.1个月 vs 连续给药组未达到(HR 1.69,95%CI 0.87-3.28,p=0.121)。
  • 治疗前检出BRAFV600E ctDNA与更差的总生存相关(HR 2.55,95%CI 1.25-5.21,p=0.01)。

核心结论

  • INTERIM研究结果与近期其他临床试验一致,即间歇给药不能改善BRAF+MEK抑制剂的疗效。

研究设计与样本

  • INTERIM是一项2期随机试验,纳入计划开始达拉非尼联合曲美替尼治疗的BRAFV600突变晚期黑色素瘤患者79例(间歇给药组39例,连续给药组40例)。
  • 间歇给药方案为达拉非尼第1-21天、曲美替尼第1-14天,每28天为一周期;连续给药组接受连续给药。
  • 复合主要终点包括无进展生存期和生活质量,次要终点包括客观缓解率、总生存期和不良事件。
  • 采用微滴数字PCR(ddPCR)检测BRAFV600E ctDNA,以突变等位基因频率>1%作为检测阈值。

主要发现

  • 患者中位年龄67岁,65%为AJCC(第7版)IV期M1c,29%有脑转移;中位随访19个月。
  • 间歇给药组中位无进展生存期8.5个月 vs 连续给药组10.7个月(HR 1.39,95%CI 0.79-2.45,p=0.255)。
  • 间歇给药组中位总生存期18.1个月 vs 连续给药组未达到(HR 1.69,95%CI 0.87-3.28,p=0.121)。
  • 间歇给药组客观缓解率57% vs 连续给药组77%。
  • 间歇给药组治疗相关不良事件发生率76% vs 连续给药组88%,但>3级不良事件发生率53% vs 42%;生活质量有利于连续给药组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BRAF+MEK inhibitors extend life expectancy of patients with BRAFV600 mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this limitation. INTERIM was a phase 2 trial evaluating an intermittent dosing regimen. METHODS: Patients with BRAFV600 mutant advanced melanoma due to start dabrafenib+trametinib were randomised to receive either continuous (CONT), or intermittent (INT; dabrafenib d1-21, trametinib d1-14 every 28 days) dosing. A composite primary endpoint included progression-free survival (PFS) and quality of life (QoL). Secondary endpoints included response rate (ORR), overall survival (OS) and adverse events (AEs). Mutant BRAFV600E ctDNA was measured by droplet digital PCR (ddPCR), using mutant allele frequency of > 1 % as the detection threshold. RESULTS: 79 patients (39 INT, 40 CONT) were recruited; median age 67 years, 65 % AJCC (7th ed) stage IV M1c, 29 % had brain metastases. With 19 months median follow-up, INT was inferior in all efficacy measures: median PFS 8.5 vs 10.7mo (HR 1.39, 95 %CI 0.79-2.45, p = 0.255); median OS 18.1mo vs not reached (HR 1.69, 95 %CI 0.87-3.28, p = 0.121), ORR 57 % vs 77 %. INT patients experienced fewer treatment-related AEs (76 % vs 88 %), but more grade > 3 AEs (53 % vs 42 %). QoL favoured CONT. Detection of BRAFV600E ctDNA prior to treatment correlated with worse OS (HR 2.55, 95 %CI 1.25-5.21, p = 0.01) in both arms. A change to undetected during treatment did not significantly predict better OS. CONCLUSION: INTERIM findings are consistent with other recent clinical trials reporting that intermittent dosing does not improve efficacy of BRAF+MEK inhibitors.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dayimu A, Gupta A, Matin RN, et al. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM). Eur J Cancer. 2023. PMID: 38029480. doi:10.1016/j.ejca.2023.113455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。